ACADIA Pharmaceuticals (NASDAQ:ACAD) Shareholders Have Endured a 37% Loss From Investing in the Stock Five Years Ago
Yahoo FinanceApr 28 09:38 ET
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Yahoo FinanceApr 24 16:05 ET
ACADIA Pharmaceuticals (NASDAQ:ACAD) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
Simply Wall StApr 24 10:42 ET
Express News | Acadia Pharmaceuticals Announces Trofinetide New Drug Submission For Treatment Of Rett Syndrome Accepted For Filing And Priority Review By Health Canada
Moomoo 24/7Apr 22 09:06 ET
Express News | ACADIA Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Moomoo 24/7Apr 22 09:04 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
BusinesswireApr 19 16:05 ET
Express News | ACADIA Pharmaceuticals Inc : Needham Cuts Target Price to $30 From $32: Needham Cuts Target Price to $30 From $32
Moomoo 24/7Apr 19 05:35 ET
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (A
BenzingaApr 17 16:19 ET
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table provides
BenzingaApr 10 16:01 ET
Express News | Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Moomoo 24/7Apr 10 09:33 ET
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
Yahoo FinanceApr 10 01:28 ET
Taysha Draws Bullish View at Piper Sandler on Lead Asset
Seeking AlphaApr 9 15:16 ET
Rett Syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven res
PR NewswireApr 9 10:01 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
TipRanksApr 9 06:40 ET
Express News | Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target
Moomoo 24/7Apr 9 06:28 ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
TipRanksApr 8 22:40 ET
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at
BusinesswireApr 2 16:05 ET
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, A
BusinesswireApr 1 16:05 ET
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing
Stephen Davis, Director, CEO, on March 27, 2024, sold 17,714 shares in Acadia Pharmaceuticals (ACAD) for $317,081. Following the Form 4 filing with the SEC, Davis has control over a total of 118,842 s
MT NewswiresMar 28 10:01 ET
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
Yahoo FinanceMar 28 02:00 ET
No Data
No Data